Hepatotoxicity: A scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action

Abstract The ability of a compound to cause adverse effects to the liver is one of the most common reasons for drug development failures and the withdrawal of drugs from the market. Such adverse effects can vary tremendously in severity, leading to an array of possible drug-induced liver injuries (DILIs). As a result, it is not surprising that drug development has evolved into a complex and multifaceted process including methods aiming to identify potential liver toxicities. Unfortunately, hepatotoxicity remains one of the most complex and poorly understood areas of human toxicity; thus it is a significant challenge to identify potential hepatotoxins. The performance of existing methods to identify hepatotoxicity requires improvement. The current study details a scheme for generating chemical categories and the development of structural alerts able to identify potential hepatotoxins. The study utilized a diverse 951-compound dataset and used structural similarity methods to produce a number of structurally restricted categories. From these categories, 16 structural alerts associated with observed human hepatotoxicity were developed. Furthermore, the mechanism(s) by which these compounds cause hepatotoxicity were investigated and a mechanistic rationale was proposed, where possible, to yield mechanistically supported structural alerts. Alerts of this nature have the potential to be used in the screening of compounds to highlight potential hepatotoxicity, whilst the chemical categories themselves are important in applying read-across approaches. The scheme presented in this study also has the potential to act as a knowledge generator serving as an excellent starting platform from which to conduct additional toxicological studies.

[1]  C. Stephens,et al.  Mechanisms of drug-induced liver injury , 2014, Current opinion in allergy and clinical immunology.

[2]  N. Kaplowitz,et al.  Drug-Induced Liver Disease Ed. 3 , 2013 .

[3]  Nigel Greene,et al.  The development of structure-activity relationships for mitochondrial dysfunction: uncoupling of oxidative phosphorylation. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  F. Rodeghiero,et al.  Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines , 2012, Leukemia & lymphoma.

[5]  I. Hung,et al.  A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B , 2012, PloS one.

[6]  Katarzyna R Przybylak,et al.  In silico models for drug-induced liver injury – current status , 2012, Expert opinion on drug metabolism & toxicology.

[7]  R. Orlando,et al.  The Effect of Drugs on Bile Flow and Composition , 1986, Drugs.

[8]  Sular nisoldipine.  Pharmacokinetics and Metabolism , 2012 .

[9]  M T D Cronin,et al.  A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity , 2011, Critical reviews in toxicology.

[10]  R. Peralta,et al.  Influence of tamoxifen on gluconeogenesis and glycolysis in the perfused rat liver. , 2011, Chemico-biological interactions.

[11]  Ivan Rusyn,et al.  Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. , 2011, Chemical research in toxicology.

[12]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[13]  A. Stepan,et al.  Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.

[14]  Y. Yoo,et al.  Induction of apoptosis by cordycepin via reactive oxygen species generation in human leukemia cells. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[15]  Hossein Khalili,et al.  Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[16]  R. Weimann,et al.  Review of liver injury associated with dietary supplements , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[17]  Brigitte Vollmar,et al.  Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. , 2010, World journal of gastroenterology.

[18]  Tiago Rodrigues,et al.  On the mechanisms of phenothiazine-induced mitochondrial permeability transition: Thiol oxidation, strict Ca2+ dependence, and cyt c release. , 2010, Biochemical pharmacology.

[19]  E. Cadenas,et al.  Regulation of Mitochondrial Glutathione Redox Status and Protein Glutathionylation by Respiratory Substrates* , 2010, The Journal of Biological Chemistry.

[20]  D. Adams,et al.  Mechanisms of immune-mediated liver injury. , 2010, Toxicological Sciences.

[21]  E. Soares,et al.  Acute hepatotoxicity caused by enalapril: a case report. , 2010, Journal of gastrointestinal and liver diseases : JGLD.

[22]  P. Ganey,et al.  Intrinsic versus Idiosyncratic Drug-Induced Hepatotoxicity—Two Villains or One? , 2010, Journal of Pharmacology and Experimental Therapeutics.

[23]  Daniel L Villeneuve,et al.  Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.

[24]  Alexander Tropsha,et al.  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. , 2010, Chemical research in toxicology.

[25]  P. Hirsova,et al.  Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats. , 2010, Toxicology.

[26]  D A Smith,et al.  Role of reactive metabolites in drug-induced hepatotoxicity. , 2010, Handbook of experimental pharmacology.

[27]  T. Theruvath,et al.  Mitochondrial calcium and the permeability transition in cell death. , 2009, Biochimica et biophysica acta.

[28]  R. Fontana,et al.  A Review on ACE-inhibitor Associated Hepatoxicity: 372 , 2009 .

[29]  A. Kalgutkar,et al.  Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. , 2009, Chemical research in toxicology.

[30]  R Scott Obach,et al.  Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. , 2008, Chemical research in toxicology.

[31]  E. Sullivan,et al.  Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures , 2008 .

[32]  A Jawaid,et al.  Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis , 2008, The Pharmacogenomics Journal.

[33]  P. Beaune,et al.  Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[34]  A. Duarte-Rojo,et al.  Anabolic–androgenic steroids and liver injury , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[35]  Kamiyama,et al.  Toxicity in Rats , 2008 .

[36]  S. H. Hussaini,et al.  Idiosyncratic drug-induced liver injury: an overview , 2007, Expert opinion on drug safety.

[37]  M. Ross,et al.  Human carboxylesterases and their role in xenobiotic and endobiotic metabolism , 2007, Journal of biochemical and molecular toxicology.

[38]  Yvonne Will,et al.  Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[39]  S. Verma,et al.  Hepatotoxicity associated with dietary supplements containing anabolic steroids. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  Charlotte A. Ashby,et al.  Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling1 , 2007, The Journal of Immunology.

[41]  D. Pessayre,et al.  Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver , 2007, Journal of Pharmacology and Experimental Therapeutics.

[42]  M. Givens,et al.  Antibacterial and Antifungal Agents , 2007 .

[43]  Donald P. McDonnell,et al.  International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors , 2006, Pharmacological Reviews.

[44]  E. Cavalieri,et al.  Catechol Quinones of Estrogens in the Initiation of Breast, Prostate, and Other Human Cancers , 2006, Annals of the New York Academy of Sciences.

[45]  Rick Moore,et al.  Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. , 2006, The Journal of biological chemistry.

[46]  M. Boccadoro,et al.  Corticosteroids can reverse severe imatinib-induced hepatotoxicity. , 2006, Haematologica.

[47]  M. Alonso,et al.  Validated HPLC Method for Cynarin Determination in Biological Samples , 2006 .

[48]  C. Laggner,et al.  Why drugs fail--a study on side effects in new chemical entities. , 2005, Current pharmaceutical design.

[49]  Katie Chan,et al.  Drug-induced mitochondrial toxicity , 2005, Expert opinion on drug metabolism & toxicology.

[50]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[51]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[52]  B. Monia,et al.  Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. , 2005, Diabetes.

[53]  William M. Lee,et al.  Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions , 2005, Toxicologic pathology.

[54]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[55]  L. Kaguni.  DNA Polymerase γ, The Mitochondrial Replicase1 , 2004 .

[56]  P. LeWitt.  Subcutaneously administered apomorphine , 2004, Neurology.

[57]  C. Tuquet,et al.  Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria , 2004, Cell Biology and Toxicology.

[58]  N. Kaplowitz,et al.  Drug-Induced Liver Injury , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  E. Rodríguez-Garay.  Cholestasis: human disease and experimental animal models. , 2003, Annals of hepatology.

[60]  Albert P. Li,et al.  A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. , 2002, Chemico-biological interactions.

[61]  S. Duan,et al.  Barbiturates Induce Mitochondrial Depolarization and Potentiate Excitotoxic Neuronal Death , 2002, The Journal of Neuroscience.

[62]  K. Penttilä,et al.  Effects of entacapone and tolcapone on mitochondrial membrane potential. , 2002, European journal of pharmacology.

[63]  Neil Kaplowitz,et al.  Drug-Induced Liver Disease , 2002 .

[64]  G. Gores,et al.  Mechanisms of hepatotoxicity. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[65]  P. Desmond,et al.  Hepatotoxicity of Antimicrobial Agents , 2002, Seminars in liver disease.

[66]  M. Balakirev,et al.  Mitochondrial injury by disulfiram: two different mechanisms of the mitochondrial permeability transition. , 2001, Chemico-biological interactions.

[67]  J. Custódio,et al.  Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. , 2001, Toxicology and applied pharmacology.

[68]  P. Neven,et al.  Tamoxifen, screening and new oestrogen receptor modulators. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[69]  P. Anzenbacher,et al.  Cytochromes P450 and metabolism of xenobiotics , 2001, Cellular and Molecular Life Sciences CMLS.

[70]  H. Lorenz,et al.  Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? , 2000, Arthritis and rheumatism.

[71]  K. Knights,et al.  In vitro metabolism of acitretin by human liver microsomes: evidence of an acitretinoyl-coenzyme A thioester conjugate in the transesterification to etretinate. , 2000, Biochemical pharmacology.

[72]  T. Kakuda,et al.  Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. , 2000, Clinical therapeutics.

[73]  J. Custódio,et al.  Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure. , 2000, Biochimica et biophysica acta.

[74]  A. Baeza-Squiban,et al.  Protection from cytotoxic effects induced by the nitrogen mustard mechlorethamine on human bronchial epithelial cells in vitro. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[75]  J. Boyer,et al.  Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. , 2000, Gastroenterology.

[76]  S. Simon,et al.  A Mechanism for Tamoxifen-mediated Inhibition of Acidification* , 1999, The Journal of Biological Chemistry.

[77]  S. Dehal,et al.  Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[78]  D. Phillips,et al.  Idoxifene derivatives are less reactive to DNA than tamoxifen derivatives, both chemically and in human and rat liver cells. , 1999, Carcinogenesis.

[79]  B. K. Park,et al.  α-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro , 1999 .

[80]  J. Muñoz,et al.  [Pyrimethamine and sulfadoxine as a preventive treatment for Pneumocystis carinii and Toxoplasma encephalitis]. , 1999, Enfermedades infecciosas y microbiologia clinica.

[81]  F. Kuipers,et al.  Differential effects of 17alpha-ethinylestradiol on the neutral and acidic pathways of bile salt synthesis in the rat. , 1999, Journal of lipid research.

[82]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.

[83]  M. Duffel,et al.  Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. , 1998, Cancer research.

[84]  F. Beland,et al.  Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. , 1997, Carcinogenesis.

[85]  G. Lambert,et al.  Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. , 1997, Clinical chemistry.

[86]  S. Shibutani,et al.  Identification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxytamoxifen. , 1997, Chemical research in toxicology.

[87]  C. Gartung,et al.  Ethinyl estradiol cholestasis involves alterations in expression of liver sinusoidal transporters. , 1996, The American journal of physiology.

[88]  J. Custódio,et al.  The effect of the anticancer drugs tamoxifen and hydroxytamoxifen on the calcium pump of isolated sarcoplasmic reticulum vesicles. , 1996, Toxicology in vitro : an international journal published in association with BIBRA.

[89]  B. Chernyak,et al.  The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. , 1996, European journal of biochemistry.

[90]  B. Chernyak,et al.  Modulation of the Mitochondrial Permeability Transition Pore by Pyridine Nucleotides and Dithiol Oxidation at Two Separate Sites (*) , 1996, The Journal of Biological Chemistry.

[91]  S. Dehal,et al.  Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. , 1996, Cancer research.

[92]  J. Custódio,et al.  A reliable and rapid procedure to estimate drug partitioning in biomembranes. , 1991, Biochemical and biophysical research communications.

[93]  G. Hofhaus,et al.  The respiratory-chain NADH dehydrogenase (complex I) of mitochondria. , 1991, European journal of biochemistry.

[94]  D. Jay.  Inhibition of membrane-bound succinate dehydrogenase by disulfiram , 1991, Journal of bioenergetics and biomembranes.

[95]  R. Renkawitz,et al.  The glucocorticoid receptor. , 1991, Biochimica et biophysica acta.

[96]  G. Dodin,et al.  Ditercalinium, a nucleic acid binder, inhibits the respiratory chain of isolated mammalian mitochondria. , 1990, Cancer research.

[97]  J. Boyer,et al.  Hepatic toxicity of Vitamin A and synthetic retinoids , 1990, Journal of gastroenterology and hepatology.

[98]  M. Murphy,et al.  Slip and leak in mitochondrial oxidative phosphorylation. , 1989, Biochimica et biophysica acta.

[99]  C. Zazueta,et al.  Extensive Ca2+ release from energized mitochondria induced by disulfiram , 1989, Journal of bioenergetics and biomembranes.

[100]  B. de Kruijff,et al.  Effects of adriamycin on respiratory chain activities in mitochondria from rat liver, rat heart and bovine heart. Evidence for a preferential inhibition of complex III and IV. , 1987, Biochimica et biophysica acta.

[101]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[102]  R. Brasseur,et al.  Adriamycin inactivates cytochrome c oxidase by exclusion of the enzyme from its cardiolipin essential environment. , 1982, Biochemical and biophysical research communications.

[103]  T. Singer.  [57] Mitochondrial electron-transport inhibitors , 1979 .

[104]  T. Singer.  Mitochondrial electron-transport inhibitors. , 1979, Methods in enzymology.

[105]  H. Zimmerman,et al.  Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .

[106]  E. Dybing,et al.  Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis. , 1976, Molecular pharmacology.

[107]  P. Klite,et al.  5-fluorocytosine: an oral antifungal compound. A report on clinical and laboratory experience. , 1972, Annals of internal medicine.

[108]  P. Guth,et al.  THE PHENOTHIAZINETRANQUILIZERS: BIOCHEMICAL AND BIOPHYSICAL ACTIONS. , 1964, International review of neurobiology.

[109]  J. Rhoads,et al.  The Influence of Local Treatment of Burns on Liver Function. , 1945, Annals of surgery.

[110]  A. V. Jackson.  LIVER NECROSIS IN BURNS TREATED WITH TANNIC ACID , 1944 .

[111]  C. R. Lam,et al.  Tannic Acid and the Treatment of Burns: An Obsequy. , 1944, Annals of surgery.